Table 3.

Distribution of CP-susceptibility gene mutations in patients with and without adverse pregnancy outcomes

	Patients with adverse pregnancy outcomes (n = 38)	Patients without adverse pregnancy outcomes (n = 122)	P
Gene mutations, n (%)	29 (76.3)	66 (54.1)	0.015
SPINK1 mutations	22 (57.9)	45 (36.9)	0.022
c.194 + 2T>C	22 (57.9)	41 (33.6)	0.007
c.101A>G	1 (2.6)	3 (2.5)	1.000
c.202C>T	0 (0.0)	1 (0.8)	1.000
c.206C>T	1 (2.6)	0 (0.0)	0.238
c.75C>G	1 (2.6)	0 (0.0)	0.238
PRSS1 mutations	7 (18.4)	17 (13.9)	0.499
c.86A>T	2 (5.3)	2 (1.6)	0.239
c.346C>T	0 (0.0)	2 (1.6)	1.000
c.364C>T	0 (0.0)	1 (0.8)	1.000
c.365G>A	3 (7.9)	3 (2.5)	0.293
c.623G>C	2 (5.3)	9 (7.4)	0.934
CTRC mutations	1 (2.6)	5 (4.1)	1.000
c.180C>T	0 (0.0)	4 (3.3)	0.573
c.181G>A	0 (0.0)	1 (0.8)	1.000
c.649G>A	1 (2.6)	0 (0.0)	0.238
c.703G>A	1 (2.6)	0 (0.0)	0.238
CFTR mutations	2 (5.3)	14 (11.5)	0.421
c.1865G>A	0 (0.0)	1 (0.8)	1.000
c.2909G>A	0 (0.0)	2 (1.6)	1.000
c.2936A>C	1 (2.6)	1 (0.8)	0.420
c.3205G>A	0 (0.0)	2 (1.6)	1.000
c.3635delT	0 (0.0)	1 (0.8)	1.000
c.4056G>C	1 (2.6)	7 (5.7)	0.733

CP, chronic pancreatitis.